Contains Nonbinding Recommendations

Draft Guidance on Haloperidol

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Haloperidol

Dosage Form; Route: Tablets; Oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 2 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional Comments: To prevent severe dystonia, subjects should be pre-medicated with benztropine tablets, 1 mg every 10 to 12 hours beginning 4 to 6 hours before dosing with haloperidol and continuing for a total of 4 doses to provide coverage during periods of substantial haloperidol levels. In the event of breakthrough acute dystonia, diphenhydramine hydrochloride 50 mg could be administered IM or IV.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 2 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional Comments: See above.

Analyte to measure (in appropriate biological fluid): Haloperidol in plasma

Bioequivalence based on (90% CI): Haloperidol

Waiver request of in-vivo testing: 0.5 mg, 1 mg, 5 mg, 10 mg and 20 mg based on (i) acceptable bioequivalence studies on the 2 mg strength, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the formulations across all strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of the test and reference

Recommended Dec 2008; Revised Feb 2019
products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).